31,427 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Aviva PLC

Aviva PLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,427 shares of the biotechnology company's stock, valued at approximately $539,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Vanguard Group Inc. grew its holdings in ADMA Biologics by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after buying an additional 80,302 shares during the period. Geode Capital Management LLC increased its position in ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after purchasing an additional 50,399 shares during the last quarter. Perpetual Ltd acquired a new position in ADMA Biologics during the fourth quarter worth approximately $62,300,000. Lord Abbett & CO. LLC purchased a new position in ADMA Biologics during the third quarter worth approximately $61,858,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 4.3 %

ADMA stock traded down $0.95 during midday trading on Wednesday, reaching $21.20. 3,953,935 shares of the company's stock traded hands, compared to its average volume of 3,601,101. ADMA Biologics, Inc. has a fifty-two week low of $5.91 and a fifty-two week high of $23.64. The business has a 50-day moving average price of $17.96 and a two-hundred day moving average price of $18.19. The company has a market capitalization of $5.01 billion, a P/E ratio of 75.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.